Clinical Trials Offered

Below is a list of our currently enrolling studies at Metroplex Clinical Research Center as well as upcoming studies.  If you have any questions, please do not hesitate to give us a call at (214) 879-6737 or contact us using the CONTACT US form.

 
Search:
Indication:
 
* Click the plus sign ( + ) to see more information
IndicationsTrial IDTrial StatusTrial NameTrial TitleTrial CommentsClinicalTrials.gov ID
Anklyosing SpondilitisUCBAS0005EnrollingA Phase 3 Open-Label(Part A) followed by a Randomized, double-blind, placebo study(Part B) to evaluate maintenance of remission in subjects with active axial spondyloarthritis receiving either Cimzia 200mg Q2W or 200mg Q4W as compared to placebo (C-OPTIMISE)A Phase 3 Open-Label(Part A) followed by a Randomized, double-blind, placebo study(Part B) to evaluate maintenance of remission in subjects with active axial spondyloarthritis receiving either Cimzia 200mg Q2W or 200mg Q4W as compared to placebo (C-OPTIMISE) NCT02505542
Giant Cell ArteritisGSK2973327EnrollingA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arthritis.A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arthritis. NCT02531633
Lower back pain, OsteoperosisRegeneron R475-PN-1524EnrollingA Randomized, Double-blind, multi-dose, placebo-controlled phase 2/3 study to evaluate the efficacy and safety of Fasinumab in patients with moderate to severe chronic Low Back PainA Randomized, Double-blind, multi-dose, placebo-controlled phase 2/3 study to evaluate the efficacy and safety of Fasinumab in patients with moderate to severe chronic Low Back Pain NCT02620020
LupusAstraZeneca D3461C00004EnrollingA Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active System Lupus ErythematosusA Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active System Lupus Erythematosus NCT02446899
Osteoarthritis of the Knee, Osteoarthritis of the HipRegeneron 1523EnrollingRegeneron 1523 OA Hip or KneeRegeneron 1523 OA Hip or Knee NCT02683239
Psoriasis, Psoriatic ArthritisAmgen 20130207EnrollingA Phase 3 Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic ArthritisA Phase 3 Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis NCT02376790
Rheumatoid Arthritis20130108EnrollingStudy of ABP798 in Treating Moderate or Severe Rheumatoid Arthritis Compared to RituximabA Randomized, Double-blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis NCT02792699
Rheumatoid ArthritisAbbVie M13-542EnrollingA Study to Compare ABT-494 to Placebo in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs (SELECT-BEYOND)A Study to Compare ABT-494 to Placebo in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs (SELECT-BEYOND) NCT02706847
Rheumatoid ArthritisAbbVie M13-549EnrollingA Phase 3, Randomized, Double-blind study comparing ABT 494 to placebo in subjects with moderately to severely active Rheumatoid Arthritis who are on a stable dose of csDMARDs and have an inadequate response to csDMARDsA Phase 3, Randomized, Double-blind study comparing ABT 494 to placebo in subjects with moderately to severely active Rheumatoid Arthritis who are on a stable dose of csDMARDs and have an inadequate response to csDMARDs NCT02675426
Rheumatoid ArthritisAbbVie M14-465EnrollingA Phase 3, Randomized, Double-blind study comparing ABT 494 to placebo to Humira in subjects with moderately to severely active Rheumatoid Arthritis who are on a stable background of MTX and who have had an inadequate response to MTXA Phase 3, Randomized, Double-blind study comparing ABT 494 to placebo to Humira in subjects with moderately to severely active Rheumatoid Arthritis who are on a stable background of MTX and who have had an inadequate response to MTX NCT02629159
Rheumatoid ArthritisBMS IM101-550 AVERT-2EnrollingA Phase 3B, Randomized, Double-Blind clinical trial to evaluate the efficacy and safety of Orencia subcutaneous in combination with MTX compared to MTX monotherapy in achieving clinical remission in adults with early Rheumatoid Arthritis who are MTX naiveA Phase 3B, Randomized, Double-Blind clinical trial to evaluate the efficacy and safety of Orencia subcutaneous in combination with MTX compared to MTX monotherapy in achieving clinical remission in adults with early Rheumatoid Arthritis who are MTX naive NCT02504268
SclerodermaROCHE WA29767EnrollingA Phase 3 Randomized, double-blind, placebo-controlled study to assess the safety of Actemra vs. placebo in patients with Systemic SclerosisA Phase 3 Randomized, double-blind, placebo-controlled study to assess the safety of Actemra vs. placebo in patients with Systemic Sclerosis NCT02453256
Sjogrens SyndromeBiogen 999SJ001EnrollingA biomarker study to determine the Gene Expression Signatures of Salivary Gland and Blood in Subjects with Incident Primary Sjogren’s Syndrome, Subjects with Sicca, and Healthy VolunteersA biomarker study to determine the Gene Expression Signatures of Salivary Gland and Blood in Subjects with Incident Primary Sjogren’s Syndrome, Subjects with Sicca, and Healthy Volunteers NCT02422407